Edition:
India

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

6.00CAD
15 Dec 2017
Change (% chg)

$-0.07 (-1.15%)
Prev Close
$6.07
Open
$6.10
Day's High
$6.15
Day's Low
$5.96
Volume
113,106
Avg. Vol
59,088
52-wk High
$14.17
52-wk Low
$2.75

Chart for

About

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead... (more)

Overall

Beta: 2.13
Market Cap(Mil.): $689.24
Shares Outstanding(Mil.): 83.54
Dividend: --
Yield (%): --

Financials

BRIEF-Aurinia Pharmaceuticals Added To The Nasdaq Biotech Index

* AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights

15 Nov 2017

BRIEF-Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​

* Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​

24 Oct 2017

BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise

* Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​

20 Oct 2017

BRIEF-Aurinia Pharmaceuticals reports Q2 loss per share $‍0.03​

* Aurinia reports second quarter 2017 financial results, and provides operational highlights

11 Aug 2017

BRIEF-Aurinia Pharmaceuticals resolves temporary non-compliance with Nasdaq's audit committee composition rule

* Aurinia resolves temporary non-compliance with Nasdaq's audit committee composition rule Source text for Eikon: Further company coverage:

13 Jul 2017

Earnings vs. Estimates